Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Purchased by Two Star Manager LLC

Two Star Manager LLC grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 63.6% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 19,793 shares of the medical research company's stock after buying an additional 7,693 shares during the period. Thermo Fisher Scientific makes up 4.8% of Two Star Manager LLC's portfolio, making the stock its 11th largest holding. Two Star Manager LLC's holdings in Thermo Fisher Scientific were worth $10,297,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Thurston Springer Miller Herd & Titak Inc. increased its position in shares of Thermo Fisher Scientific by 74.7% during the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 166 shares of the medical research company's stock valued at $86,000 after purchasing an additional 71 shares during the last quarter. Hennion & Walsh Asset Management Inc. increased its position in Thermo Fisher Scientific by 80.5% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 4,696 shares of the medical research company's stock valued at $2,443,000 after acquiring an additional 2,094 shares during the last quarter. Decker Retirement Planning Inc. purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at $43,000. Wedge Capital Management L L P NC boosted its stake in shares of Thermo Fisher Scientific by 4.1% during the 4th quarter. Wedge Capital Management L L P NC now owns 706 shares of the medical research company's stock worth $367,000 after purchasing an additional 28 shares during the period. Finally, Merit Financial Group LLC grew its holdings in Thermo Fisher Scientific by 54.4% during the 4th quarter. Merit Financial Group LLC now owns 9,851 shares of the medical research company's stock valued at $5,125,000 after purchasing an additional 3,470 shares during the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Evercore ISI dropped their target price on Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a research report on Thursday, April 24th. Wells Fargo & Company cut their price objective on Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating on the stock in a research report on Thursday, April 24th. Morgan Stanley lifted their target price on Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an "overweight" rating in a research report on Friday, January 31st. Royal Bank of Canada cut their price target on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. Finally, Raymond James reissued an "outperform" rating and issued a $667.00 price objective (up from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday, February 3rd. Five equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $607.43.

Insider Transactions at Thermo Fisher Scientific

In related news, SVP Michael A. Boxer sold 3,775 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the completion of the transaction, the senior vice president now directly owns 10,816 shares in the company, valued at $5,759,736.32. The trade was a 25.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the transaction, the chief executive officer now owns 115,174 shares of the company's stock, valued at $59,506,950.58. The trade was a 7.99% decrease in their position. The disclosure for this sale can be found here. Insiders sold 14,075 shares of company stock valued at $7,305,942 in the last quarter. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Stock Down 0.1%

NYSE TMO traded down $0.45 during midday trading on Tuesday, hitting $413.47. 2,141,884 shares of the company traded hands, compared to its average volume of 1,845,527. Thermo Fisher Scientific Inc. has a 52 week low of $390.50 and a 52 week high of $627.88. The company's 50-day simple moving average is $449.99 and its 200-day simple moving average is $508.22. The company has a market cap of $156.08 billion, a PE ratio of 25.01, a price-to-earnings-growth ratio of 2.99 and a beta of 0.82. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.10 by $0.05. The company had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The firm's quarterly revenue was up .2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $5.11 earnings per share. As a group, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were given a dividend of $0.43 per share. The ex-dividend date was Friday, March 14th. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.42%. Thermo Fisher Scientific's dividend payout ratio is presently 10.09%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.